Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Cancer Discovery2022Vol. 13(2), pp. 298–311
Citations Over TimeTop 1% of 2022 papers
Samantha B. Kemp, Noah Cheng, Nune Markosyan, Rina Sor, Il‐Kyu Kim, Jill Hallin, Jason Shoush, Liz Quinones, Natalie V. Brown, Jared B. Bassett, Nikhil Joshi, Salina Yuan, Molly Smith, William P. Vostrejs, Kia Z. Perez-Vale, Benjamin Kahn, Feiyan Mo, Timothy R. Donahue, Caius G. Radu, Cynthia Clendenin, James G. Christensen, Robert H. Vonderheide, Ben Z. Stanger
Abstract
Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC. See related commentary by Redding and Grabocka, p. 260. This article is highlighted in the In This Issue feature, p. 247.
Related Papers
- → The Role of Exosomes in Pancreatic Cancer(2019)91 cited
- → Oxidative Stress and Cytokines in the Pathogenesis of Pancreatic Cancer(2014)49 cited
- → Secreted protein acidic and rich in cysteine inhibits the growth of human pancreatic cancer cells with G1 arrest induction(2014)8 cited
- → Gadofullerene nanoparticles extend survival rate and down-regulate thrombin expression in orthotopic pancreatic cancer(2021)4 cited
- SOX7 expression correlates with better prognosis in pancreatic cancer patients and is negatively related to pancreatic cancer associated diabetes.(2017)